Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF Receivables Turnover is 1.66 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Futura Medical ranks worse than 81.33% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Futura Medical's Revenue for the
six
months ended in Dec. 2025 was $0.93 Mil. Futura Medical's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.56 Mil.
Hence, Futura Medical's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.66.
Futura Medical (OTCPK:FAMDF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Futura Medical Receivables Turnover Related Terms
Futura Medical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Futura Medical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FAMDF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Futura Medical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Futura Medical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Futura Medical (FAMDF) has a Receivables Turnover of 1.66 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Futura Medical and its competitors. According to the industry distribution chart, Futura Medical ranks #684 out of 841 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Futura Medical's Receivables Turnover too high?
Futura Medical's current Receivables Turnover is 1.66. The Biotechnology industry median Receivables Turnover is 5.29. Futura Medical's value of 1.66 is 68.6% below this industry median. Based on the distribution chart, Futura Medical ranks #684 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Futura Medical's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #684 out of 841 companies for Receivables Turnover. This places Futura Medical in the lower half of its industry. The industry median Receivables Turnover is 5.29. Futura Medical's value of 1.66 is 68.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Futura Medical's current Receivables Turnover of 1.66 is 68.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Futura Medical and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current Receivables Turnover is 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.01 — trading 87.5% below its estimated fair value. The current Receivables Turnover is 1.66 and 68.6% below the Biotechnology industry median of 5.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Futura Medical (FAMDF), the current Receivables Turnover is 1.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
